Valuation
- Market cap
- 169,317,000
- Revenue TTM
- $7,150,000
- Net income TTM
- $-20,600,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -288.11%
- Debt to equity
- 0.00
Trading
- Volume
- 337,300
- Avg volume
- 344,790
- Day's range
- $2.98 – $3.08
- Shares out
- 57,009,000
- Stochastic %K
- 12%
- Beta
- 0.92
- Analysts
- Strong Sell
- Price target
- $7.71
Company profile
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in...
Show more
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 551 321 2234
- Website
- https://ir.whitehawktx.com
- Address
- 2 Headquarters Plaza, East Building 11th Floor, Morristown, United States
Latest news
No headlines yet.
